2024-11-22 05:00:00
France has more than 8 million people suffering from obesity. In this context, the arrival on the market of anti-obesity treatments Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) represents new hope for patients. Because until now, if you had difficulty losing weight, your options were very limited. These medications are praised by some obesity specialists for their effectiveness. Other health professionals remain cautious and emphasize the lack of perspective on their long-term effects.
In this video, we return to the active ingredient of these new drugs, which imitate a digestive hormone naturally produced by the human body: glucagon-like peptide-1 (GLP-1). This hormone, discovered in the 1980s, acts in particular on insulin secretion and the feeling of satiety.
We also explain the conditions to be eligible for this type of treatment in France, which can only be prescribed by doctors specializing in endocrinology, diabetology or nutrition. Wegogy and Mounjaro are designed to be used as second-line treatment, after failure of nutritional treatment.
To find out more about these new treatments and the excitement they are causing in the financial markets, you will find a complete breakdown below.
Read later
“Understand in three minutes”
The explanatory videos that make up the “Understand in three minutes” series are produced by the Vertical Videos department of the Monde. Broadcast primarily on platforms such as TikTok, Snapchat, Instagram and Facebook, they aim to put major events into context in a short format and make the news accessible to everyone.
The contributions area is reserved for subscribers.
Subscribe to access this discussion space and contribute to the discussion.
Contribute
Reuse this content
1732263202
#antiobesity #drugs #Wegogy #Mounjaro #work #Understand #minutes
What are the potential long-term effects of using anti-obesity medications like Wegovy and Mounjaro?
**Interview with Dr. Emily Rousseau, Obesity Specialist**
*Date: 2024-11-22*
**Host:** Good morning, Dr. Rousseau. With over 8 million people in France suffering from obesity, it seems the introduction of anti-obesity medications like Wegovy and Mounjaro could be a game-changer. Can you share your thoughts on these new treatments?
**Dr. Rousseau:** Good morning! Yes, the emergence of Wegovy and Mounjaro is certainly significant. These medications utilize GLP-1 receptor agonists, which mimic the action of glucagon-like peptide-1, a hormone that affects appetite and glucose metabolism. This offers a new avenue for those struggling to lose weight, especially since previous options were limited and often not very effective.
**Host:** Some specialists are praising these medications for their effectiveness, while others express caution about their long-term effects. What are the concerns surrounding these treatments?
**Dr. Rousseau:** That’s a great point. While evidence suggests that these medications can lead to substantial weight loss and improvement in metabolic health, there are valid concerns about the long-term effects. We still need more longitudinal studies to fully understand the implications of prolonged use and any potential side effects. The full profile of these drugs—both benefits and risks—will become clearer as more patients use them over time.
**Host:** How do you think these medications will change the treatment landscape for obesity in France?
**Dr. Rousseau:** They represent a shift towards a more holistic approach in treating obesity, shifting away from just diet and exercise to include pharmaceutical options. This could empower many patients who have struggled with weight loss, offering them a legitimate medical approach rather than relying solely on lifestyle changes that they may find difficult to adhere to. However, it’s essential for these treatments to be part of a comprehensive weight management program that includes lifestyle modifications as well.
**Host:** Given their potential, what advice would you give to patients considering these treatments?
**Dr. Rousseau:** I would encourage patients to consult with their healthcare provider to discuss their individual circumstances and options. It’s important to have realistic expectations and understand that while these medications can aid in weight loss, they are not a magic solution. Emphasis should still be placed on sustainable lifestyle changes. Monitoring and support should continue as part of their overall weight management plan.
**Host:** Thank you, Dr. Rousseau, for your insights on these transformative treatments. It’s clear there is much hope for patients facing obesity, coupled with a need for careful consideration of all aspects involved.
**Dr. Rousseau:** Thank you for having me! It’s important to keep the conversation going about obesity and the resources available to help manage it effectively.
*End of Interview*